BlackRock
PLRX icon

BlackRock’s Pliant Therapeutics PLRX Stock Holding History

BlackRock’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Buy
1,151,214
+54,784
+5% +$66.7K ﹤0.01% 4270
2026
Q1 		$1.38M Buy
1,096,430
+23,158
+2% +$29.2K ﹤0.01% 4233
2025
Q4 		$1.31M Sell
1,073,272
-347,591
-24% -$522K ﹤0.01% 4230
2025
Q3 		$2.1M Sell
1,420,863
-709,656
-33% -$1.08M ﹤0.01% 4074
2025
Q2 		$2.47M Sell
2,130,519
-3,111,240
-59% -$4.4M ﹤0.01% 4007
2025
Q1 		$7.08M Buy
5,241,759
+61,782
+1% +$375K ﹤0.01% 3488
2024
Q4 		$68.2M Sell
5,179,977
-38,988
-0.7% -$532K ﹤0.01% 2280
2024
Q3 		$58.5M Buy
5,218,965
+247,326
+5% +$3.09M ﹤0.01% 2377
2024
Q2 		$53.4M Buy
4,971,639
+316,254
+7% +$4.08M ﹤0.01% 2370
2024
Q1 		$69.4M Sell
4,655,385
-146,132
-3% -$2.41M ﹤0.01% 2265
2023
Q4 		$87M Buy
4,801,517
+478,916
+11% +$7.28M ﹤0.01% 2159
2023
Q3 		$75M Sell
4,322,601
-84,219
-2% -$1.46M ﹤0.01% 2155
2023
Q2 		$79.9M Buy
4,406,820
+2,578,692
+141% +$61M ﹤0.01% 2196
2023
Q1 		$48.6M Buy
1,828,128
+332,626
+22% +$9.47M ﹤0.01% 2465
2022
Q4 		$28.9M Buy
1,495,502
+126,382
+9% +$2.64M ﹤0.01% 2827
2022
Q3 		$28.6M Buy
1,369,120
+483,034
+55% +$9.24M ﹤0.01% 2833
2022
Q2 		$7.1M Sell
886,086
-812,126
-48% -$5.2M ﹤0.01% 3664
2022
Q1 		$11.9M Buy
1,698,212
+10,338
+0.6% +$105K ﹤0.01% 3479
2021
Q4 		$22.8M Buy
1,687,874
+135,882
+9% +$2.16M ﹤0.01% 3187
2021
Q3 		$26.2M Sell
1,551,992
-5,730
-0.4% -$122K ﹤0.01% 3103
2021
Q2 		$45.4M Sell
1,557,722
-117,100
-7% -$3.65M ﹤0.01% 2764
2021
Q1 		$65.9M Buy
1,674,822
+819,249
+96% +$26.6M ﹤0.01% 2440
2020
Q4 		$19.4M Buy
855,573
+371,294
+77% +$9.31M ﹤0.01% 3022
2020
Q3 		$11M Buy
484,279
+398,792
+466% +$9.97M ﹤0.01% 3172
2020
Q2 		$2.77M Buy
+85,487
New +$2.27M ﹤0.01% 3726

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock's PLRX Position: Q2 2026 in Review

BlackRock increased its Pliant Therapeutics (PLRX) stake by 5% in Q2 2026, buying an estimated $66.7K and bringing the position to 1,151,214 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #4270.

BlackRock first reported a position in PLRX in Q2 2020 and has held it in 25 quarters since. The position peaked at $87M in Q4 2023. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • BlackRock held 1,151,214 shares of Pliant Therapeutics worth $1.31M as of Q2 2026.
  • BlackRock bought 54,784 Pliant Therapeutics shares in Q2 2026, an estimated $66.7K.
  • Pliant Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4270 holding.
  • BlackRock first reported a position in Pliant Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • BlackRock's Pliant Therapeutics position peaked at $87M in Q4 2023.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.